This is a repository copy of Pharmaceutical Pricing : Early Access, The Cancer Drugs Fund and the Role of NICE.
|
|
- Victoria Casey
- 6 years ago
- Views:
Transcription
1 This is a repository copy of Pharmaceutical Pricing : Early Access, The Cancer Drugs Fund and the Role of NICE. White Rose Research Online URL for this paper: Version: Accepted Version Monograph: Claxton, Karl Philip orcid.org/ (2016) Pharmaceutical Pricing : Early Access, The Cancer Drugs Fund and the Role of NICE. Discussion Paper. Policy & Research Briefing. Centre for Health Economics, University of York Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by ing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. eprints@whiterose.ac.uk
2 P P E Access, The Cancer Drugs Fund R NICE Policy & Research Briefing March 2016 A B C Acknowlegements: T transcript of a speech given at the Westminster Health Forum in January T comments received from Mark Sculpher M S A responsibility of the author. Project team: Karl Claxton. F Centre for Health Economics, University of York Karl.Claxton@york.ac.uk T unsustainable, it s unsustainable for the NHS and it s also unsustainable I NHS access and an early return on their investments. The real problem has been, and remains, the discrepancy NHS An evidenced based and accountable assessment of the N I H Care Excellence (NICE) has done an excellent job over the years in taking account of other evidence to NICE the NHS. Not just the cost of the drug itself but all future NHS costs, H NHS I health could have been gained NHS W opportunity costs are likely to be across the NHS. Recent research NHS expenditure on the health of all NHS T NHS resources adds one Quality Adjusted Life Year (QALY) to the NHS S NHS year is likely to lead to the loss QALY increased mortality and reduced survival in cancer, circulatory, in neurological diseases and mental What does this mean for the NHS? One thing it means is that increasing expenditure on the NHS appears to be very good QALY NHS W have evidence that every QALY gained or lost through spending NHS I NHS pays for itself. Recent research also suggests that NHS expenditure Y QALY NHS improvements in health. If you do, reallocate public expenditure. I NICE What does this mean for NICE? NICE says it uses a threshold range QALY This range is based on the values implied by the decisions NICE but over recent years it generally per QALY. In fact, the most recent evidence indicates that, on average, QALY T NICE more harm than good to
3 QALY QALY T NICE accelerate the net harm and increase the scale of the net harm done to the rest of the NHS. T A A R C D F V Based Assessment, have all failed to address this fundamental problem. Instead they appear to ignore or deny it. That denial F NHS been ignored by NICE is profoundly mistaken. The principle of the methods of NICE appraisal. Some suggest that the measure of health adopted by NICE QALY B W A C NHS S W S NHS W T is that prices are not determined by the costs. The costs T I there is a normal return on those investments. Costs don t I S NHS supported and investment in research and development UK D Much more important is investment in the type of basic environment in the UK is the best place to develop and U UK T C D F The Cancer Drugs Fund has been a real lesson T CDF T T CDF I B A E QALY CDF to one. A I P P R S PPRS I NHS N NHS W CDF NICE chance they might T NICE T CDF it has in the past. T T NICE and become eligible for CDF funding because there remains T to price as high as possible. All manufacturers should expect CDF T CDF as are as high as possible. Of course, there also remains a NICE R I A T QALY QALY NHS QALY
4 establish a high price at the outset. P I CDF E W I T N I evidence based medicine. T NHS CDF W N A mechanism to take a more sensible approach is available. I NICE NICE should only be used in the context of research and make NICE MRC NICE T NICE R in research means that the type of randomised trials that I NICE or rejected. O that have access to current NHS care and those that also W I C D F outcomes. T P P R S T T P P R S agreed caps on NHS spending on branded drugs. Rebates I I NHS I and can be agreed. W PPRS W NHS I I produce valuable drugs and are responsible in their pricing. F I to retain the greatest share of capped expenditure. Also, prescribing costs that fall directly on their budgets. As a T PPRS A manufacturers could point to the fact that the caps on expenditure have been exceeded and should be increased. U NHS NHS UK D H T NHS T T T I A NICE PPRS T NHS
5 T I NHS I rebates. Manufacturers also need to be able to set prices UK T T PPRS NHS asking manufacturers to change their prices for the UK. M For example, NHS England and the Department of Health T of commissioner and prescribers facing high prices falling A are agreed and local prescribing costs are fully reimbursed, NHS T NICE on the evidence. Manufacturers can then decide if they I I NICE I transparent assessment of the evidence. L NICE NHS F NHS O F NHS expenditure on mortality outcomes. The important thing is that this research demonstrates that it is an empirical A ongoing evidence based and accountable assessment of clear and predictable signal they need in making good NHS References: C K M S S M R N S E H S M N I H C E H W E F C K S M P S C AJ C NHS H E J J L K S G R C D E gains and losses from marginal changes to NHS expenditure in England. Health E S G M J R MD C AJ N I C E BMJ D H D N F Y T NICE H E S E N A O I C D F HC S S C K B A B MJ C AJ M C C W S V NHS B M J F G SC C KP P SJ S MJ D H E F C K P S L L B L G S M K C I NICE of health technologies only in the context of an appropriately designed H T A M K C S M C K B L G S P S U R R D C S D S A J R V S A C K OFT VBP QED H E M C K S M C S V NHS C H E U Y CHE R P Centre for Health Economics University of York Heslington York YO10 5DD UK Tel: Fax: che-news@york.ac.uk
The consequences of uncertainty and the implications for policy. Karl Claxton 21/11/2017
The consequences of uncertainty and the implications for policy Karl Claxton 21/11/2017 Overview Why does uncertainty matter? Clinical value of evidence Linking endpoints to outcome Dealing with costs
More informationValue based pricing for the NHS
Value based pricing for the NHS Karl Claxton Department of Economics and Related Studies, Centre for Health Economics, University of York. www.york.ac.uk/inst/che Some key questions What is value in the
More informationThis is a repository copy of Consumption strategies and motivations of Chinese consumers: The case of UK sustainable luxury fashion.
This is a repository copy of Consumption strategies and motivations of Chinese consumers: The case of UK sustainable luxury fashion. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk//
More informationValue-Based Pricing Working Party #1: Briefing for DH presentation
Value-Based Pricing Working Party #1: Briefing for DH presentation This document provides background material for the DH presentation to the first Working Party on the implementation of value assessment
More informationInvestigation into the Cancer Drugs Fund
Report by the Comptroller and Auditor General Department of Health and NHS England Investigation into the Cancer Drugs Fund HC 442 SESSION 2015-16 17 SEPTEMBER 2015 4 Key facts Investigation into the Cancer
More informationThis is a repository copy of The role of budget speech : A Malaysian government study.
This is a repository copy of The role of budget speech : A Malaysian government study. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/110742/ Version: Accepted Version Article:
More informationNICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health
NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE s technology appraisal and highly specialised technologies
More informationThis is a repository copy of The link between health care spending and health outcomes for the new English Primary Care Trusts.
This is a repository copy of The link between health care spending and health outcomes for the new English Primary Care Trusts. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/39809/
More informationPublications Gateway Reference Question and Answer document for the NHS on the Pharmaceutical Price Regulation Scheme (PPRS)
Question and Answer document for the NHS on the Pharmaceutical Price Regulation Scheme (PPRS) 1 Question and Answer document for the NHS on the Pharmaceutical Price Regulation Scheme (PPRS) May 2014. What
More informationMedicine Management NELCSU Document
For inclusion in NHS Provider contracts as a document relied on: CCG Commissioned National Tariff Payment System (NTPS) Formerly Payment by Results Excluded Drugs & Devices Policy 2017/19 Amendment history:
More informationCCG Policy on Primary Care Rebate Schemes (PCRS)
CCG Policy on Primary Care Rebate Schemes (PCRS) 1. Introduction A number of manufacturers have established rebate schemes for drugs used in primary care. Their motive for this could be speculated on for
More informationPolicy for Approving Primary Care Prescribing Rebate Schemes
Policy for Approving Primary Care Prescribing Rebate Schemes 2/1/2017 Version Control Responsible Officer: Clinical Lead: Author: Hazel Buchanan, Director of Operations Dr Parm Panesar Hazel Buchanan,
More informationQuality of Health Care and the Design of the Basic Benefit Package Lessons from Overseas
Quality of Health Care and the Design of the Basic Benefit Package Lessons from Overseas Michael Drummond Centre for Health Economics, University of York Outline of Presentation Efficiency and the use
More informationThis is a repository copy of Asymmetries in Bank of England Monetary Policy.
This is a repository copy of Asymmetries in Bank of England Monetary Policy. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/9880/ Monograph: Gascoigne, J. and Turner, P.
More informationQuick Reference Guide: Key Health Care Reform Requirements Affecting Plan Sponsors
Quick Reference Guide: Key Health Care Reform Requirements Affecting Plan Sponsors The following is a brief summary of some of the key requirements affecting group health plan sponsors. This is only a
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationINTO ESTIMATES OF COST PER QALY: November Allan Wailoo, Professor of Health Economics
INCORPORATING WIDER SOCIETAL BENEFITS INTO ESTIMATES OF COST PER QALY: IMPLICATIONS OF VALUE BASED PRICING FOR NICE. REPORT BY THE DECISION SUPPORT UNIT November 2012 Allan Wailoo, Professor of Health
More information3.2. CCG Board Paper Summary Sheet. Agenda Item. DETAILS Part 1 (Open) X Part 2 (Closed) Title of Paper Pharmaceutical Rebate Schemes Meeting
CCG Board Paper Summary Sheet 3.2 DETAILS Part 1 (Open) X Part 2 (Closed) Agenda Item Title of Paper Pharmaceutical Rebate Schemes Meeting CCG Board Date 5 st November 2015 Executive Lead Dawn Clarke,
More informationCASE COMMENTS. Introduction
208 CASE COMMENTS The UK Pharmaceutical Price Regulation Scheme (PPRS) and the Statutory Regulations: An Overview and Outline of How the Schemes May Impact the Life Sciences Industry CHRISTIAN HILL,* PAUL
More informationCoverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions
VALUE IN HEALTH 15 (2012) 570 579 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval POLICY PERSPECTIVES Coverage with Evidence Development, Only in Research, Risk
More informationThis is a repository copy of Personalization in the health care system : do personal health budgets impact on outcomes and cost?.
This is a repository copy of Personalization in the health care system : do personal health budgets impact on outcomes and cost?. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/76720/
More informationTHE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL INTRODUCED BY WHITE, STREET, BARTOLOTTA, COSTA, FONTANA AND BREWSTER, APRIL 18, 2017 AN ACT
PRIOR PRINTER'S NO. PRINTER'S NO. THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL No. Session of 0 INTRODUCED BY WHITE, STREET, BARTOLOTTA, COSTA, FONTANA AND BREWSTER, APRIL 1, 0 SENATOR WHITE, BANKING
More informationThe simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry
New University of Lisboa From the SelectedWorks of Pedro P Barros December, 2007 The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry Pedro P Barros, Universidade
More informationThe ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs
The ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs Steven D. Pearson, MD, MSc The ICER Value Framework Takes a population level perspective as opposed to trying to serve
More informationBREVE 7 EXPLICIT PRIORITY SETTING IN NEW ZEALAND AND THE UK
BREVE 7 EXPLICIT PRIORITY SETTING IN NEW ZEALAND AND THE UK Presentation by Tommy Wilkinson. April 2014 A series on policies and methods based on presentations for experts. Prepared by CRITERIA, a knowledge
More informationDods Monitoring: Health Service Medical Supplies (Costs) Bill. Briefing following Second Reading
Dods Monitoring: Health Service Medical Supplies (Costs) Bill Briefing following Second Reading October 2016 Background The Bill seeks to address the current imbalance between the two regulatory schemes
More informationIs the QALY a Necessary Evil? Michael Drummond Centre for Health Economics, University of York
Is the QALY a Necessary Evil? Michael Drummond Centre for Health Economics, University of York Outline of Presentation Some background. What s good about the QALY? What adjustments are required to QALYs?
More informationCost-benefit analysis and social impact bond feasibility analysis for the Birmingham Be Active scheme
Cost-benefit analysis and social impact bond feasibility analysis for the Birmingham Be Active scheme Final Report December 2011 Kevin Marsh Evelina Bertranou Kunal Samanta Funded by Disclaimer In keeping
More informationACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together
ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS Supporting employees and building sustainable drug plans...together Not available in the province of Quebec INTRODUCING THE SPECIALTY DRUG PROGRAM If you
More informationWales Patient Access Scheme: Process Guidance
Wales Patient Access Scheme: Process Guidance July 2012 (Updated August 2016) This guidance document has been prepared by the Patient Access Scheme Wales Group, with support from the All Wales Therapeutics
More informationIf we had evidence based drug policy, what would it look like? Christine Godfrey Department of Health Sciences/Centre for Health Economics
If we had evidence based drug policy, what would it look like? Christine Godfrey Department of Health Sciences/Centre for Health Economics The quick version For those who have to rush off don t know currently
More informationBackground The Health Impact Fund (HIF) Characteristics of the HIF Progress
1 Background The Health Impact Fund (HIF) Characteristics of the HIF Progress 2 Millions of patients lack access to the optimal medicines because of high prices made possible by patent protection. Low
More informationYour Social Security. Disability Benefits. What You Need to Know to Collect What s Rightfully Yours
Your Social Security Disability Benefits What You Need to Know to Collect What s Rightfully Yours This guide is provided by DISABILITY ASSOCIATES, LLC ATTORNEYS AT LAW TRACEY N. PATE, MANAGING ATTORNEY
More informationStep by step guide to economic evaluation in cancer trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More informationLife, Death, and Property Rights Thomas Abraham Ivy Arcos Josh Choi Gregor Henneka Judy Im
Life, Death, and Property Rights Thomas Abraham Ivy Arcos Josh Choi Gregor Henneka Judy Im TRIPS Meeting the rising concerns of multinational companies about copying and plagiarizing of their products
More informationICER Value Assessment Framework: 1.0 to 2.0
ICER Value Assessment Framework: 1.0 to 2.0 Outline Background on ICER Version 1.0 development Conceptual basis for ICER value assessment framework Domains of value Long-term perspective (value for money)
More informationVALUE-BASED DIFFERENTIAL PRICING: EFFICIENT PRICES FOR DRUGS IN A GLOBAL CONTEXT
HEALTH ECONOMICS Health Econ. 24: 294 301 (2015) Published online 11 December 2013 in Wiley Online Library (wileyonlinelibrary.com)..3021 VALUE-BASED DIFFERENTIAL PRICING: EFFICIENT PRICES FOR DRUGS IN
More informationA policy for Bristol, North Somerset and South Gloucestershire Clinical Commissioning Groups 1
Policy for the Sponsorship of Activities and Joint Working by the Pharmaceutical Industry with Bristol, North Somerset, and South Gloucestershire Clinical Commissioning Groups A policy for Bristol, North
More informationHealth Care Reform Timeline
Health Care Reform Timeline April 7, 2010 Dear Valued Client, As your employee benefits advisor, we understand that you may have many questions and concerns regarding the recent historic health care reform
More informationMethodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur
Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur Job Bag: SAGB.SA.18.03.0294 Date of Preparation: March 2018 INTRODUCTION The European
More informationCaptureStroke Economic Case Studies White Paper
CaptureStroke Economic Case Studies White Paper CaptureStroke is the UK s leading clinical Stroke pathway software CaptureStroke is the UK s leading clinical Stroke pathway software which improves stroke
More information(2016) : 25 (8) ISSN
Morton, Alec and Adler, Amanda I. and Briggs, Andy and Bell, David and Brouwer, Werner and Claxton, Karl and Fischer, Alastair and Craig, Neil and McGregor, Peter and van Baal, Pieter (2016) Unrelated
More informationIP11: DECISION-MAKING IN HEALTH CARE BASED ON ECONOMIC EVALUATIONS: REALITY OR JUST WISHFUL THINKING? EXPERIENCES FROM 4 EUROPEAN COUNTRIES
IP11: DECISION-MAKING IN HEALTH CARE BASED ON ECONOMIC EVALUATIONS: REALITY OR JUST WISHFUL THINKING? EXPERIENCES FROM 4 EUROPEAN COUNTRIES Andreas Gerber-Grote Margreet Franken, Emelie Heintz, James P.
More informationThis is a repository copy of The Cost-Effectiveness of Population Health Checks: : have the NHS Health Checks been unfairly maligned?.
This is a repository copy of The Cost-Effectiveness of Population Health Checks: : have the NHS Health Checks been unfairly maligned?. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk//
More informationMedical Research: What s it worth? Estimating the economic benefits from medical research in the UK
Medical Research: What s it worth? Estimating the economic benefits from medical research in the UK Briefing November 2008 Summary This briefing describes the outcomes of a one-year study into the economic
More informationDisclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi
Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support
More informationCo-financing mechanisms Budget cap Pay back Risk-sharing instruments Reimbursement tax
LINKING TODAY S DECISIONS WITH TOMORROW S POSSIBILITIES: HTA: LINKING TODAY S DECISIONS WITH TOMORROW S POSSIBILITIES: A PERSPECTIVE FROM POLAND, HUNGARY, GREECE AND SERBIA A PERSPECTIVE FROM POLAND Speakers:
More informationEFFICIENCY AND TRANSPARENCY IN PRICING
1 EFFICIENCY AND TRANSPARENCY IN PRICING SHANG-PING CHEN RESEARCHER DIVISION OF MEDICAL REVIEW AND PHARMACEUTICAL BENEFITS NATIONAL HEALTH INSURANCE ADMINISTRATION (NHIA), TAIWAN 2014/10/31 Outline 2 Drug
More informationIntegrated Impact Assessment Report for Clinical Commissioning Policies
Integrated Impact Assessment Report for Clinical Commissioning Policies Policy Reference Number Policy Title Accountable Commissioner F05X02 Treatment of iron overload for transfused and non transfused
More informationThe Cost of Specialty Drugs: Payer Perspectives
ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports exploring important
More informationIs there additional value attached to health gains at the end-of-life? A re-visit
COHERE - Centre of Health Economics Research Is there additional value attached to health gains at the end-of-life? A re-visit By Dorte Gyrd-Hansen, COHERE, Department of Business and Economics & Department
More informationCHE Research Paper 148. Pricing Implications Of Non-Marginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model
Pricing Implications Of Non-Marginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model Daniel Howdon, James Lomas CHE Research Paper 148 Pricing implications of non-marginal budgetary
More informationDeposited on: 12 May 2008 Glasgow eprints Service
Fenwick, E. and Claxton, K. and Sculpher, M. (2008) The value of implementation and the value of information: combined and uneven development. Medical Decision Making 28(1):pp. 21-32. http://eprints.gla.ac.uk/4172/
More informationREPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 1698 SESSION MAY HM Treasury and Cabinet Office. Assurance for major projects
REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 1698 SESSION 2010 2012 2 MAY 2012 HM Treasury and Cabinet Office Assurance for major projects 4 Key facts Assurance for major projects Key facts 205 projects
More informationExecutive Summary for Benefit Planning
Executive Summary for Benefit Planning Insuring People and Business Since 1868 3 Executive Summary for Benefit Planning 2010 Overview On March 23, 2010, President Obama signed into law the health care
More informationThe benefits of the PBS to the Australian Community and the impact of increased copayments
The benefits of the PBS to the Australian Community and the impact of increased copayments Health Issues No 71 June 2002 Executive Summary The purpose of this paper is to argue that the Pharmaceutical
More informationPolicy for the review, acceptance and monitoring of rebate schemes offered by the pharmaceutical industry
Policy for the review, acceptance and monitoring of rebate schemes offered by the pharmaceutical industry Version: Version 6 Ratified by: Date Ratified: 25 January 2018 ame & Title of originator/author(s):
More informationWhy choose Critical Illness+?
Retirement Investments Insurance Health Why choose Critical Illness+? Please note: This guide provides brief summaries of the cover and options available. For full details you must read the policy summary
More informationPublic Health England s grant to local authorities
Report by the Comptroller and Auditor General Department of Health and Public Health England Public Health England s grant to local authorities HC 888 SESSION 2014-15 17 DECEMBER 2014 4 Key facts Public
More informationOutcomes-based reimbursement of medicines
Outcomes-based reimbursement of medicines Making markets fairer and more competitive Nigel Keohane Kathryn Petrie Outcomes-based reimbursement of medicines Nigel Keohane Kathryn Petrie Kindly sponsored
More informationThe determinants of change in the cost-effectiveness threshold
The determinants of change in the cost-effectiveness threshold [PWP 2015_01] Mike Paulden, MSc 1, James O Mahony, PhD 2, and Christopher McCabe, PhD 1 1 Department of Emergency Medicine, University of
More informationApplication form. Bupa By You. Thank you for choosing Bupa. Before you begin. For office use only. Ex Group Scheme Transfer D D M M Y Y Y Y
Application form Bupa By You Ex Group Scheme Transfer Thank you for choosing Bupa This form should be completed by you, the intermediary on behalf of your client. Please complete this application form
More informationValue based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2010.03740.x Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Adrian
More informationHealth and well-being in times of austerity
Health and well-being in times of austerity Ms Zsuzsanna Jakab WHO Regional Director for Europe Outline The context Promoting health in times of austerity Macroeconomic impacts of health Health systems
More informationVIEWpoint TAX ALERT. ACA Repeal and Replacement. House GOP Proposes To Eliminate Most ACA Taxes; Some Coverage/Credit Benefits Remain
VIEWpoint TAX ALERT Insight, Oversight and Foresight for Your Business ACA Repeal and Replacement House GOP Proposes To Eliminate Most ACA Taxes; Some Coverage/Credit Benefits Remain House Republicans
More informationPIP DATA FOR MARKET ACCESS
PIP DATA FOR MARKET ACCESS By Mark Nuijten, PhD, MD, MBA Maart 13, 2012 London, UK GENERAL TRENDS IN HEALTH CARE SYSTEMS IN EUROPE Health Care Systems Budget Constraints Inceasing demand for health care
More informationThis is a repository copy of Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.
This is a repository copy of Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/348/
More informationPrescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007
Prescription Drugs Spending Distribution and Cost Drivers Steve Kappel January 25, 2007 Introduction Why Focus on Drugs? Compared to other health care spending: Even faster annual growth Higher reliance
More informationBrief on Fair Drug Prices in New Brunswick
Brief on Fair Drug Prices in New Brunswick New Brunswick Association of Social Workers Ensuring quality professional social work services to the population of New Brunwick August 12, 2011 1-877-495-5595
More informationSummary report. Indonesian study tour to the National Institute for Health and Care Excellence, England
Summary report Indonesian study tour to the National Institute for Health and Care Excellence, England 28 th 30 th September 2015 Summary brief: Indonesia Study Tour September 2015 1 of 24 Background The
More informationPharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson
Pharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson Avalere Health An Inovalon Company April 2015 Number of News Articles Public Focus on Drug Prices Increased Dramatically
More informationThis is a repository copy of Overlaps in dimensions of poverty. White Rose Research Online URL for this paper:
This is a repository copy of Overlaps in dimensions of poverty. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/590/ Article: Bradshaw, J and Finch, N orcid.org/0000-0001-5753-1783
More informationIndian Pharmaceutical Market
Indian Pharmaceutical Market 1 New regulatory and drug pricing policies are negatively impacting growth in the Indian pharmaceutical sector, but opportunities remain Recent changes to regulatory and pricing
More informationUnrelated future costs and unrelated future benefits: Reflections on NICE Guidance to the Methods of Technology Appraisal
Unrelated future costs and unrelated future benefits: Reflections on NICE Guidance to the Methods of Technology Appraisal Keywords: health technology assessment, economic analysis, cost effectiveness analysis,
More informationCrosses the Finish Line. A presentation for the Manufacturer & Business Association
Health Care Reform Crosses the Finish Line A presentation for the Manufacturer & Business Association Background Statement of the problem 50,000,000 uninsured Healthcare costs rising at 2x 4x annual rate
More informationNHS Scotland Patient Access Scheme (PAS) Guidance
NHS Scotland Patient Access Scheme (PAS) Guidance NHS Scotland Patient Access Scheme (PAS) Guidance V5 (Last updated 26 th June 2018) Contents Page 1. Introduction 3 2. Patient Access Scheme Assessment
More informationTHE WIDENING HEALTH CARE GAP BETWEEN HIGH- AND LOW-WAGE WORKERS. Sherry Glied and Bisundev Mahato Columbia University. May 2008
I SSUE B RIEF THE WIDENING HEALTH CARE GAP BETWEEN HIGH- AND LOW-WAGE WORKERS Sherry Glied and Bisundev Mahato Columbia University May 2008 ABSTRACT: Rising health care costs affect everyone, but pose
More informationImpact Assessment (IA)
Title: 2018 Statutory Scheme Branded Medicines Pricing IA No: 9553 Lead department or agency: Department of Health and Social Care Other departments or agencies: N/A Impact Assessment (IA) Date: 12/07/2018
More informationAFFORDABLE CARE ACT. And the Aging Population Jan Figart, MS & Laura Ross-White, MSW. A Sign of the Times: Health Trends and Ethics
AFFORDABLE CARE ACT And the Aging Population Jan Figart, MS & Laura Ross-White, MSW A Sign of the Times: Health Trends and Ethics LiveStream: http://ostate.tv Learning Objectives Describe the history of
More informationAffordable Access to Medications Brief to the Department of Health Fair Drug Prices Consultation Submitted August 13, 2011
Affordable Access to Medications Brief to the Department of Health Fair Drug Prices Consultation Submitted August 13, 2011 Executive Summary and Recommendations The MS Society of Canada, Atlantic Division
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca UK Limited Registered in England No 3674842 Registered Office, 2 Kingdom Street, London,
More informationEstimating the cost of a life year using English PCT programme budgeting data and mortality rates
Estimating the cost of a life year using English PCT programme budgeting data and mortality rates Acknowledgement: This study builds on work funded by the Health Foundation. Introduction Cost of life year
More informationMinistry of Health and Long-Term Care Proposed new regulation made under the Health Sector Payment Transparency Act, 2017
Ministry of Health and Long-Term Care Proposed new regulation made under the Health Sector Payment Transparency Act, 2017 The Health Sector Payment Transparency Act, 2017 (HSPTA) is new legislation intended
More informationGet the most out of your pharmacy benefit.
Get the most out of your pharmacy benefit. The ins and outs of managing pharmacy costs (and how the right information can lead to big savings). Learn more about the Artemis Platform at: artemishealth.com
More informationWhat does the Value of Modern Medicine Say About
What does the Value of Modern Medicine Say About the $50,000/QALY Threshold? Duke/NUS Singapore September 5, 2016 Mark S. Roberts, MD, MPP Professor and Chair, Department of Health Policy and Management
More informationUnitedHealthcare Choice Plus. United HealthCare Insurance Company. Certificate of Coverage
UnitedHealthcare Choice Plus United HealthCare Insurance Company Certificate of Coverage For the Definity Health Savings Account (HSA) Plan 7PC of East Central College Enrolling Group Number: 711369 Effective
More informationProtecting the Health of New Brunswickers
Pharmasave Drugs Atlantic Ltd. is pleased to provide this submission as part of the consultation process for the New Brunswick government s Fair Drug Prices for New Brunswickers. The New Brunswick government
More informationIn This Issue (click to jump):
May 7, 2014 In This Issue (click to jump): Analysis of Trends in Health Spending 2013 2014 Spotlight on Medicare Advantage Enrollment Oncology Drug Trend Report S&P Predicts Shift from Job-Based Coverage
More informationSome remarks on Reckitt Benckiser
Some remarks on Reckitt Benckiser Philippe Choné 1 1 CREST-ENSAE October 25, 2012, ACE Conference, Paris Philippe Choné (CREST-ENSAE) Reckitt Benckiser ACE, Paris, October 25, 2012 1 / 12 1 UK: A competition-friendly
More informationPatient Resource Guide
Access Services Patient Resource Guide AstraZeneca Access 360 is committed to helping you access our medicines. This guide will provide you with information and resources to help you understand how to
More informationThe Funding Landscape for Small Biopharma Ventures,
HEALTHCARE The Funding Landscape for Small Biopharma Ventures, 2010-2015 Trends, strategies and priorities By Gaurav Misra Gaurav Misra Gaurav Misra specializes in pharmaceutical licensing, valuations
More informationBackground to the Panel
IP21: Does Overseas Experience of Managed Entry Agreements Inform the New Japanese Pricing Scheme for Medical Devices? ISPOR Asia Pacific 2018 8-11 September 2018 Tokyo, Japan Background to the Panel Managed
More informationA guide to understanding the medical scheme fees tax credit
A guide to understanding the medical scheme fees tax credit A guide to understanding the medical scheme fees tax credit 1 TABLE OF CONTENTS 1. INTRODUCTION... 3 2. WHAT ARE THE CHANGES?... 3 3. THE CHANGES
More informationIC Chapter 34. Limited Service Health Maintenance Organizations
IC 27-13-34 Chapter 34. Limited Service Health Maintenance Organizations IC 27-13-34-0.1 Application of certain amendments to chapter Sec. 0.1. The amendments made to section 12 of this chapter by P.L.69-1998
More informationFair Drug Prices for Nova Scotians
Fair Drug Prices for Nova Scotians September 2010 Fair Drug Prices for Nova Scotians September 2010 The Problem Nova Scotians pay too much for prescription drugs. In Nova Scotia, we pay more for generic
More informationUnitedHealthcare Choice Plus. UnitedHealthcare Insurance Company. Certificate of Coverage
UnitedHealthcare Choice Plus UnitedHealthcare Insurance Company Certificate of Coverage For the Health Savings Account (HSA) Plan 7PA of Educators Benefit Services, Inc. Enrolling Group Number: 717578
More informationAn Employer s Guide to Health Care Reform
An Employer s Guide to Health Care Reform Background On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act (PPACA). Less than a week later, Congress passed the
More informationPrecision Medicine. A Health Economic perspective
Precision Medicine. A Health Economic perspective Lieven Annemans Ghent University Lieven.annemans@ugent.be April 2018 1 Exponential technology exponential cost? http://medicalfuturist.com 2 Total public
More informationManchester Health and Care Commissioning. Finance Committee. Terms of Reference
Manchester Health and Care Commissioning Finance Committee Terms of Reference 1.0 Name The Committee shall be known as the Finance Committee. 2.0 Overview The Finance Committee forms a key element of the
More informationNATIONAL INSURANCE CONTRIBUTIONS BILL
NATIONAL INSURANCE CONTRIBUTIONS BILL EXPLANATORY NOTES INTRODUCTION 1. These explanatory notes relate to the National Insurance Contributions Bill as introduced in the House of Commons on 12th November
More information